Prolonium

Prolonium

SCHEMBL1650849

C[N+](C)(C)CC(O)C[N+](C)(C)C.[I-].[I-]

nearest known ligand 0.50

Full drug profile on Sugi Atlas →

Known targets — ChEMBL curated mechanism

ACHECHRM1CHRM3CHRNA1CHRNB1CHRNDCHRNECHRNG

The experimentally established mechanism targets of Prolonium. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CHRM1 known ✓ P11229 2/20 0.36
CHRM3 known ✓ P20309 1/20 0.35
MAPT P10636 3/20 0.50
SLC22A16 Q86VW1 1/20 0.50
TSHR P16473 3/20 0.36
CHRM2 P08172 2/20 0.36
CHRM4 P08173 2/20 0.36
TBXA2R P21731 1/20 0.36
LMNA P02545 4/20 0.35
SMN1; SMN2 Q16637 2/20 0.35
CPT2 P23786 1/20 0.35
CPT1A P50416 1/20 0.35
CHRM5 P08912 1/20 0.35
CYP2C9 P11712 1/20 0.35
GALR3 O60755 1/20 0.35
BLM P54132 1/20 0.35
PSMD14 O00487 1/20 0.32
PLA2G1B P04054 1/20 0.32
HSP90AA1 P07900 1/20 0.32
MMP2 P08253 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Prolonium SCHEMBL1649967 0.96 MAPT (0.52) MAPTSLC22A16TSHRCHRM2CHRM4
Prolonium SCHEMBL11723705 0.92 MAPT (0.50) MAPTSLC22A16TSHRCHRM2CHRM4
Prolonium SCHEMBL5705670 0.92 MAPT (0.50) MAPTSLC22A16TSHRCHRM2CHRM4
Prolonium SCHEMBL2889745 0.92 MAPT (0.57) MAPTSLC22A16TSHRCHRM2CHRM4
SCHEMBL13380702 0.86 MAPT (0.52) MAPTSLC22A16TSHRCHRM2CHRM4
Iodide SCHEMBL4083174 0.83 LMNA (0.47) MAPTSLC22A16TSHRCHRM2CHRM4
Iodide SCHEMBL9421128 0.81
Iodide SCHEMBL23501735 0.81 MAPT (0.42) MAPTSLC22A16TSHRCHRM2CHRM4
Iodide SCHEMBL28809264 0.81 MAPT (0.42) MAPTSLC22A16TSHRCHRM2CHRM4
SCHEMBL15761654 0.81 MAPT (0.42) MAPTSLC22A16TSHRCHRM2CHRM4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 78 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-103191491-A Packing material, and purpose and manufacturing method thereof ZHA HONGMEI 2013-07-10 CN claimed
CN-1751703-A Injection for treating ophthalmopathy DUAN YADONG (CN) 2006-03-29 CN claimed
CN-120736810-B AF film layer with high hardness and high wear resistance, glass product, preparation method and application 湖南天氟新材料有限公司 2025-11-07 CN disclosed
CN-120736810-A AF film layer with high hardness and high wear resistance, glass product, preparation method and application 湖南天氟新材料有限公司 2025-10-03 CN disclosed
CN-111886592-B Method and system for performing inlining on sliced data sets 谷歌有限责任公司 2025-04-22 CN disclosed
CN-118939685-A Query statement self-connection elimination method, device, equipment and storage medium 中电科金仓(北京)科技股份有限公司 2024-11-12 CN disclosed
EP-4388874-A1 PARTICULATE WEED CONTROL Bind-X GmbH (DE) 2024-06-26 EP disclosed
CN-117790035-A Slurry curing system containing radioactive elements 中国原子能科学研究院 2024-03-29 CN disclosed
US-20240090506-A1 SURFACE MODIFICATION TO REGULATE PLANT GROWTH BIND-X INTERNATIONAL GMBH (DE) 2024-03-21 US disclosed
CN-117461511-A Method for promoting growth and development of fir seedlings through moss coverage 中国科学院成都生物研究所 2024-01-30 CN disclosed
EP-4250922-A1 SURFACE MODIFICATION TO REGULATE PLANT GROWTH Bind-X GmbH (DE) 2023-10-04 EP disclosed
US-20020102215-A1 Diagnostic/therapeutic agents NYCOMED IMAGING AS 2002-08-01 US disclosed
US-20020102217-A1 Diagnostic/therapeutic agents NYCOMED IMAGING AS 2002-08-01 US disclosed
US-6331289-B1 ULTRASOUND CONTRAST AGENTS, SUSPENSION IN AQUEOUS CARRIER LIQUID OF A REPORTER COMPRISING GAS-CONTAINING OR GAS-GENERATING MATERIAL, AGENT CAPABLE OF FORMING AT LEAST TWO TYPES OF BINDING PAIRS WITH TARGET; REPORTER BEING CONJUGATED NYCOMED IMAGING AS (NO) 2001-12-18 US disclosed
CN-1323592-A Dressed composite medicine for treating vitreous body diseases ZHU WEIGUO (CN) 2001-11-28 CN disclosed
US-6264917-B1 MIXTURE OF GAS FILLED MICROBUBBLES AND RELEASING AGENT NYCOMED IMAGING AS (NO) 2001-07-24 US disclosed
US-6261537-B1 TARGETS AND ULTRASOUND DIAGNOSIS OF ACTIVE MATERIALS, AQUEOUS CARRIER LIQUIDS, CARRIERS AND FILM FORMING SURFACTANT PHOSPHATIDES NYCOMED IMAGING AS (NO) 2001-07-17 US disclosed
CN-1225271-A Pearl eyesight improvement drops contg vitamin C CHEN ZHONGRONG (CN) 1999-08-11 CN disclosed
CN-1225271-A Pearl eyesight improvement drops contg vitamin C CHEN ZHONGRONG (CN) 1999-08-11 CN disclosed
CN-1135357-A Medicinal composition for treatment of unmatured catarct ZHU JIN (CN) 1996-11-13 CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020102215-A1 Diagnostic/therapeutic agents BID, FUS, FABP1 CHRM1 4583/4885CHRM3 4193/4885MAPT 2239/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.